Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Ono Targets over 800 Billion Yen in FY2035 Sales under Growth Scenario: CEO
July 1, 2025
- SymBio Seeks EU Clearance to Launch Global PIII Trial of Brincidofovir
July 1, 2025
- Glaucoma Drug Gla-Alpha Approved in Singapore: Kowa
July 1, 2025
- Celltrion’s Stelara Biosimilar to Hit Shelves on July 8
July 1, 2025
- Sanofi Releases Typhim Vi, First Typhoid Vaccine in Japan
July 1, 2025
- Servier Files Tibsovo for Biliary Tract Cancer in Japan
July 1, 2025
- ASKA Rolls Out Contraceptive Pill Slinda in Japan
July 1, 2025
- 17 of 23 Japan Drug Makers Hike Average Pay in FY2024, 7 Firms Break 10-Million-Yen Mark
July 1, 2025
- J-TEC Targets 1,000 Knee OA Cases Per Year for JACC: CEO
June 30, 2025
- Rakuten, Taiwan’s Orient EuroPharma Ink Photoimmunotherapy Deal
June 30, 2025
- Asahi Kasei Kicks Off Japan PIII for Recomodulin for CIPN
June 30, 2025
- Moderna Japan Files Updated COVID Shot for Age 11 and Under
June 30, 2025
- LP.8.1-Adapted Novavax COVID Vaccine Filed in Japan: Takeda
June 30, 2025
- Fuji Pharma Filed for OTC Approval of Emergency Contraceptive Last October
June 27, 2025
- Chugai Files Alecensa for ALK-Positive Solid Tumors in Japan
June 27, 2025
- Kyowa Kirin Wins Japan Nod for Lumicef Pen Injector
June 27, 2025
- ASKA Launches Japan PIII of Relugolix Combo for Endometriosis
June 26, 2025
- Japan Approves Crysvita Prefilled Syringe: Kyowa Kirin
June 26, 2025
- SanBio Pushes Back Shipment Approval Timeline for Cell Therapy Akuugo
June 26, 2025
- Takeda Zeros in on US Successor Ahead of 2026 CEO Transition
June 26, 2025
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…